key: cord-1031679-iej5gewq
authors: Bhari, Vikas Kumar; Kumar, Durgesh; Kumar, Surendra; Mishra, Rajeev
title: SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes
date: 2020-11-05
journal: Biochem Biophys Rep
DOI: 10.1016/j.bbrep.2020.100844
sha: 13373e5547bf1c83a589e550df5312b5b0850798
doc_id: 1031679
cord_uid: iej5gewq

The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite COVID-19 pandemic got center stage at present time, however very little research being explores, which increase our knowledge in context with how SARS-CoV-2 infection affect cancer a cellular level. Therefore, in light of the ACE-2 as an important contributor of COVID-19 global, we analyzed correlation between ACE2 and tumor immune infiltration (TIL) level and the type markers of immune cells were investigated in breast cancer subtypes by using TIMER database. Our findings shed light on the immunomodulatory role of ACE2 in the luminal A subtype which may play crucial role in imparting therapeutic resistance in this cancer subtype.

Prediction of clinical behaviors and patient outcomes in breast cancer is very difficult and its heterogeneity makes it more complicated. [1] . The heterogeneous nature of breast cancer is reflected by different staging systems and histopathologic classification [2] . Gene expression profiling is the major criterion for intrinsic classification molecular subtypes of breast cancer known as luminal A, luminal B, HER2-enriched and basal-like highlighting the importance of different treatment responses, therefore, advocating for different therapeutic strategies [1, 3, 4] . Immune cells are inseparable components of the tumor microenvironment of breast cancer and are reported to be associated with prognosis and survival [5] [6] [7] . Tumorinfiltrating immune cells (TIC) has been correlated with better outcome and response to adjuvant therapies in breast cancer [8] . The immune components are identified to correlate with the prognosis of breast cancer and its treatment strategy. [9] .

However, there is no proof that a single immune cell will play the same role among all four subtypes [10] , which makes it mandatory to evaluate each breast cancer subtype.

The unexpected arrival of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has broadly and badly impacted all aspects of life including cancer patients. This disease has rapidly spread to at least 235 countries, with nearly 41 million confirmed cases resulting in nearly 1,128,325 confirmed deaths as of October 22, 2020 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). The coronavirus receptor angiotensin-converting enzyme 2 (ACE2) has been recognized as an entry and interaction receptor (entry gate) for the SARS-CoV-2 virus [11] , therefore, ACE2 has been accountable for the pathogenesis for COVID-19. Ever since the transmission of SARS-CoV2 emerged in China, receptor-mediated entry of SARS-CoV2 has been studied extensively [12, 13] . The RBD of the spike protein of SARS-CoV2 is responsible for the recognition of the ACE2 receptor and TMPRSS2, a serine protease is employed for S Protein priming [14] [15] [16] . organs do not behave in a regular pattern which is one of the matter of deep concern for different clinical COVID-19 disease outcomes [19] , suggesting more research is needed to widen therapeutic window. The ACE2 is widely ubiquitously distributed and highly expressed in various tissue such as heart, kidney, brain, testis, and cardiovascular-relevant tissues [20] . Being highly expressed in these tissues, ACE2 plays a major role in modulation of blood pressure, renal and cardiac functions, therefore its receptor alteration led major cardiac and renal pathophysiology associated disease [21] . Renin-angiotensin-aldosterone system (RAAS) inhibitors, which include angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II receptor type 1 blockers (ARBs) are widely used for treatment of hypertension, heart failure and coronary heart disease. Among all these diseases the major concern is associated with cardiovascular disease which is clinical managed by RAAS inhibitors such as ACEIs and ARBs [22, 23] . One of the primary concerns is that use of ACEIs and ARBs, increases the surface expression of ACE2 which will ultimately led to increased susceptibility towards COVID-19

infection as this will facilitate entry of SARS-CoV-2. On the contrary one retrospective multi-center study showed that lower mortality risk among the COVID-19 patients comorbid with hypertension treated with ACEIs and ARBs, warranting further research needed in this field [24] .

Recntaly it has been reported that cancer patients might be more susceptible to severe infection [25] , however, this scenario might be contradicted as ACE2 expression varies in different cancer types [26] . Analysis of ACE2 expression levels in different tumor cells not only helps in understanding us about the susceptibility of COVID-19 but also provides useful information about the possible consequence of ACEIs in driving/preventing tumor growth. Given this situation, we use publically available cancer genomics datasets [27] to understand the prevalence of ACE2 receptor in different types of cancer patients with COVID-19, which can be valuable in specific targeting and support the ongoing fight with SARS-CoV-2.

In this study, we first compare the expression of ACE2 in normal, breast cancer patients, and in different stages by using UACLAN and UCSC Xena browser database. After analyzing expression, the relationship between ACE2 and TIL levels in different breast cancer subtypes was investigated using the Tumor Immune 

University of California Santa Cruz (UCSC) Xena browser (https://xenabrowser.net) was used to compare the mRNA expression of ACE2 between breast cancer and normal patients and ACE2 expression among breast cancer subtypes [28] . TCGA TARGET GTEx study (n=1278) was selected to compare ACE2 expression in tumor samples vs. normal samples. After selecting this study, we used a filter option to narrow down the samples associated only with TCGA breast invasive carcinoma and GTEx breast. RSEM norm count dataset was used for the analysis and values were downloaded as log 2 (norm_count +1). To investigate the ACE2 in breast cancer subtypes, TCGA Breast Cancer (BRCA) (n=1247) was used. IlluminaHiSeq dataset was used for the analysis and values were download as log 2 (norm_count +1).

UALCAN database was used to visualize the transcript per million of ACE2 based on breast cancer individual stage. The statistical significance table was provided by the website. (http://ualcan.path.uab.edu/analysis.html) [29] .

TIMER 2.0 was used to investigate the ACE2 TIL in breast cancer and its subtypes.

It is a comprehensive database that can illustrate the immunomodulation across various cancer types (http://timer.cistrome.org) [30, 31] . We evaluated the correlation of ACE2 with TIL (NK cells, Dendritic cells, Neutrophils, and T-cell regulatory) in breast cancer subtypes. After this, the correlation of ACE2 with the immune cell type markers of TLRs, macrophage, monocytes, dendritic cells, neutrophils, and NK cells in breast cancer subtypes was confirmed. Tumor purity was used for P-value correction in the case of immune cell correlation analysis. According to correlation values, the heat map was generated by using a web application for comprehensive metabolomics data analysis and interpretation, MetaboAnalyst (http://www.metaboanalyst.ca) [32] .

J o u r n a l P r e -p r o o f 7 Data integration and statistical analysis were performed using GraphPad Prism 8.4.3. Box plots were generated for group comparison. A comparison between two groups was performed using Unpaired t-test with Welch's correction. Significance was determined by the P-value provided by the database. Spearman correlation values indicated in the tables (table 1, 2, 3 and 4) were provided by the database.

*P < 0.05; ***P < 0.001; ****P < 0.0001, was considered statistically significant.

J o u r n a l P r e -p r o o f

Carcinoma:

To understand the transcriptional expression pattern of ACE2 in breast cancer, we analyzed Its mRNA expression levels in normal tissue and tumor tissue using TCGA TARGET GTEx study (n=1278) which allows one to compare the expression using the TCGA database (tumor tissue) and GTEx database (normal tissue) in cancer patients by using UCSC Xena browser. Analyzed results suggested that the ACE2 mRNA level in breast cancer tumor tissue was significantly lower than that in normal tissue (P < 0.001; Fig 1A) . We further analyzed the ACE2 expression with the tumor stage for breast cancer patients in the TCGA database using the UALCAN portal. Consistent with the observations obtained in Fig 1A, ACE2 expression in Stage 2, 3, and 4 were significantly decreased with normal, stage 1, did not significantly differ ( Fig 1B) . As molecular subtypes of breast cancer demonstrate its biological diversity [1] , therefore we explore the ACE2 mRNA expression in these subtypes. Obtained results demonstrated that ACE2 mRNA expression was found to be downregulated in luminal (luminal A and B) breast cancer subtypes (Fig 1C) .

To investigate the correlation of ACE2 expression and TIL in breast cancer, we (Table 2 ). In

Her-2, the FCGR3B gene marker (Table 3 ) and in luminal B, NCAM1, and KLRB1 gene markers (Table 4) 

The term "cytokine storm" has become increasingly used not in the case of COVID-19, which is the main cause of Acute Respiratory Distress Syndrome (ARDS) [33] . We analyzed ACE-2 dependent cytokine modulation in breast cancer subtypes in context with its Pro or Anti-tumorigenic cytokines modulation. Heat-map was generated based on the correlation (Table 1, (Fig 4) . Evidence suggests that regulatory T cells (Tregs) correlated with worse outcome in breast cancer [34, 35] . Our results also

show the negative correlation of ACE2 with Tregs which further confirms the protective role of ACE2 in luminal A breast cancer subtype (Fig 4) .

In the present study, we identified that the transcription signature of the ACE2 (Fig 2) . The luminal A subtype is associated with a low immunological response [42] , however our results highlighted positive corealtion of ACE2 in TIL which undelying crucial immunological role of ACE2 in breast cancer, leading to poor prognosis as presence of TILs is associated poor prognosis in luminal subtypes [43] . This association is further followed by other breast cancer subtypes such as Basal and Luminal B subtypes with only few immune markers are positively correlated (Fig 2) . To understand the significance of these results in context with the current COVID-19 pandemic, we explore the various treatment options currently in use for the treatment of this disease. ACE2 receptor has been an entry point for the SARS-CoV-2 virus, therefore ACEIs are considered prime candidates for the management of this outbreak [44] . The controversy about the severity of COVID-19 is increased with the patients with comorbidities, which J o u r n a l P r e -p r o o f include cardiovascular disease, diabetes, and cancer leading to the worst outcome [45] continues unchanged, with new interpretations about this appearing almost daily. Our analysis strongly support the positive involvement of ACE2 in pro-and anti-tumor cytokines (Fig 3) and modulation of immune cells (Fig 4) in the case of luminal A subtype predicting a strong rationale for the consequence of ACEIs in promoting breast cancer progression (Fig 5) . More surprisingly in luminal, A subtype ACE2 is negatively correlated with regulatory T cells (Tregs), which regulate the host responses to infection and neoplasms [46] . Moreover, tumor cells use Tregs as a shield to protect themselves against anti-tumor immune response [46] , therefore we propose that blocking ACE2 in luminal A subtype will promote cancer progression ( Fig 5) .

Mounting evidence suggested that cytokine strom is one of the prime factor for therapeutic unpredictability and severaity of the disease leading to death [47] . As ACE2 is entry point for SARS-CoV-2, therefore inhibiting these receptor had been

shown to lower rate of disease severity in patients treated with ACEIs [48] . In these patients one of the interlukin, IL-6, was found to be lowered in peripheral blood highlighting immunomodulatory role of ACEi. Similary we also found that various interleuking also significantly corelated in luminal A breast cancer subtypes (Fig. 3) .

Furthermore, ACEIs also downregulate CD3 and CD8 cell counts which is inversely associated with with CD8 T cell functional avidity in HIV-infected people. [49] . Still the role ACEIs in immune modulation is much debateble as study reported ACEIs/ARBs prior to COVID-19 infection could reduce the severity of COVID-19 [50] which is further contradictaed by studies which does not not found any significant corelation with ACEIs/ARBs and the severity and mortality of patients with COVID-19 [51].

Here, we reported that the comparative gene expression of ACE2 each breast cancer subtypes defining its pathological role in different subtypes of breast cancer.

Our analysis suggested expression of ACE2 gene corelated with immune function.

This study is much signficant in context with current pandemic in which ACE2

inhibitor are widely used for the COVD-19 treatment. Finally, we concluded that 

Tumor Heterogeneity in Breast Cancer

Band, Histological, molecular and functional subtypes of breast cancers

Molecular portraits of human breast tumours

Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study

Tumor infiltrating lymphocytes in early breast cancer

Immune approaches to the treatment of breast cancer, around the corner?

If we build it they will come: targeting the immune response to breast cancer

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor, Science

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Comorbidity and its Impact on Patients with COVID-19., Sn Compr

SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

The emerging role of ACE2 in physiology and disease

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future

Angiotensin-converting enzyme 2 is an essential regulator of heart function

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During

ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19

Making Use of Cancer Genomic Databases

The UCSC Xena platform for public and private cancer genomics data visualization and interpretation

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

for analysis of tumor-infiltrating immune cells

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells

MetaboAnalystR 3.0: Toward an Optimized Workflow for Global Metabolomics

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells

Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: A systematic review and metaanalysis

ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway

Cancer epigenetics comes of age

Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition

Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro

Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy

Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group

Angiotensin converting enzyme-2 as therapeutic target in COVID-19

The COVID-19 Pandemic and its Impact J o u r n a l P r e -p r o o f 20 on the Cardio-Oncology Population

T-Regulatory Cells In Tumor Progression And Therapy

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

CD3 and CD8 coreceptor down-modulation are inversely associated with CD8 T cell functional avidity in humans

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

The recent outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely.The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake of this complex by the host cell is a necessary step for infection.We reported that the differential gene expression of ACE2 defines its pathological role in each molecular subtype of breast cancer differently.Our analysis suggested that the expression of ACE2 gene may relate to immune function in luminal A subtype of breast cancer.This study is much significant in context with current pandemic in which ACE2 inhibitors are widely used for the COVD-19 treatment.We concluded that the ACE inhibitor treatment in luminal A breast cancer may promote tumor progression through deregulation of immune system.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Nothing to declare J o u r n a l P r e -p r o o f